Get the Stockscreener App
5.46
1.30%
0.07
After Hours:
5.41
-0.05
-0.92%
Clene Inc stock is traded at $5.46, with a volume of 28,082.
It is up +1.30% in the last 24 hours and down -9.90% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$5.39
Open:
$5.39
24h Volume:
28,082
Relative Volume:
0.06
Market Cap:
$69.77M
Revenue:
$134.00K
Net Income/Loss:
$-33.51M
P/E Ratio:
-1.7023
EPS:
-3.2074
Net Cash Flow:
$-18.15M
1W Performance:
-4.71%
1M Performance:
-9.90%
6M Performance:
+5.20%
1Y Performance:
+49.59%
1-Day Range:
$5.29
$5.4665
1-Week Range:
$5.29
$5.96
52-Week Range:
$3.25
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
5.46 | 68.88M | 134.00K | -33.51M | -18.15M | -3.2074 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Best Nanotechnology Stocks Worth WatchingJuly 27th - MarketBeat
Clene Inc. (CLNN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clene Inc. (CLNN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Clene Inc. (CLNN) Balance Sheet - TradingKey
Top Nanotechnology Stocks To Keep An Eye OnJuly 26th - MarketBeat
Clene Inc. (CLNN) Income Statement - TradingKey
CLNN|Clene Inc.|Price:5.480|Chg%:+0.090 - TradingKey
Clene Inc. (CLNN) Slips 1.64% as Stock Consolidates Near Key SupportParabolic SAR - dars.gov.et
CLNN Options Chain — NASDAQ:CLNN - TradingView
TradingKey - TradingKey
CLNN Options Volatility — NASDAQ:CLNN - TradingView
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - Stocktwits
Nanotechnology Stocks To Watch NowJuly 24th - MarketBeat
Clene Inc. (CLNN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Best Nanotechnology Stocks To ResearchJuly 23rd - MarketBeat
Top Nanotechnology Stocks To ResearchJuly 22nd - MarketBeat
Nanotechnology Stocks To Keep An Eye OnJuly 21st - MarketBeat
When Will Clene Inc. (NASDAQ:CLNN) Breakeven? - simplywall.st
Top Nanotechnology Stocks To Watch NowJuly 20th - MarketBeat
Clene (CLNN) Proxy filing Summary - Quartr
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Clene (CLNN) Q1 2026 earnings summary - Quartr
Best Nanotechnology Stocks To Keep An Eye OnJuly 15th - MarketBeat
Enterprise value to EBIT forward of Clene Inc. – NASDAQ:CLNN - TradingView
Enterprise value to revenue forward of Clene Inc – FWB:84C0 - TradingView
Clene Inc. (CLNN) Edges Higher, Testing Key Resistance at $6.58Bollinger Expansion - dars.gov.et
Top Nanotechnology Stocks Worth WatchingJuly 11th - MarketBeat
Clene (CLNN) Q2 Virtual Investor Summit Event earnings summary - Quartr
Clene Inc. (CLNN) reports Q1 loss, misses revenue estimates - MSN
CLNN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionCost Structure Review - dars.gov.et
Enterprise value to EBIT forward of Clene Inc – FWB:84C0 - TradingView
Promising Nanotechnology Stocks To Keep An Eye OnJuly 9th - MarketBeat
Clene (CLNN) Registration Filing Summary - Quartr
Clene (CLNN) Emerging Growth Conference 92 Summary - Quartr
Clene (CLNN) Study Update Summary - Quartr
Clene (CLNN) Q4 2025 earnings summary - Quartr
Clene (CLNN) Emerging Growth Virtual Conference Summary - Quartr
Clene (CLNN) Emerging Growth Conference 89 Summary - Quartr
Clene (CLNN) 37th Annual ROTH Conference Summary - Quartr
Clene Inc. (CLNN) Q1 2026 Earnings: EPS Beat of 58.42% Surprises Estimates Amid Pre-Revenue PhaseFull Year Guidance - dars.gov.et
CLNN News | CLENE INC (NASDAQ:CLNN) - ChartMill
Clene Inc. (CLNN) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesStrong Earnings Momentum - dars.gov.et
Clene Company Profile & Introduction - Moomoo
CLNN Q1 2026 Earnings: Narrowed Loss Surprises Analysts Amidst Operational FocusAnnual Financial Report - dars.gov.et
Clene Inc.(NasdaqCM: CLNN) added to Russell Microcap Value Benchmark Index - marketscreener.com
Clene Inc.(NasdaqCM: CLNN) added to Russell Microcap Index - marketscreener.com
Clene Inc.(NasdaqCM: CLNN) added to Russell 3000E Index - marketscreener.com
Clene Inc.(NasdaqCM: CLNN) added to Russell 3000E Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Clene Inc. – NASDAQ:CLNN - TradingView
Price to earnings forward of Clene Inc. – NASDAQ:CLNN - TradingView
Price to earnings forward of Clene Inc. – BOATS:CLNN - TradingView
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):